How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation
International Journal of Cancer · 15.08.2023 · 153 (4) · 709-722
DOI: 10.1002/ijc.34464 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, 2023-03. Verfasst von Qianyu Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department of General Surgery, The 1st Medical Center, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Colorectal Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 150 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Immunotherapy, especially with immune checkpoint inhibitors (ICIs), has shown advantages in cancer treatment and is a new hope for patients who have failed multiline therapy. However, in colorectal cancer (CRC), the benefit is limited to a small subset of patients with microsatellite instability‐high (MSI‐H) or mismatch repair‐deficient (dMMR) metastatic CRC (mCRC). In addition, 45% to 60% of dMMR/MSI‐H mCRC patients showed primary or acquired resistance to ICIs. This means that these patients may have potential unknown pathways mediating immune escape. Almost all mismatch repair‐proficient (pMMR) or microsatellite‐stable (MSS) mCRC patients do not benefit from ICIs. In this review, we discuss the mechanisms of action of ICIs and their current status in CRC. We then discuss the mechanisms of primary and acquired resistance to ICIs in CRC. Finally, we discuss promising therapeutic strategies to overcome resistance to ICIs in the clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Department of General Surgery, The 1st Medical Center, Chinese PLA General Hospital, Beijing, China.
- The Second School of Clinical Medicine, Shanxi Medical University, Taiyuan, China.
- Department of General Surgery, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
- Department of General Surgery, The 7th Medical Center, Chinese PLA General Hospital, Beijing, China.
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
ORCID-Profile: Qianyu Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Q., Shen, X., Chen, G., & Du, J. (2023). How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation. International Journal of Cancer, 153(4), 709-722. https://doi.org/10.1002/ijc.34464
Vancouver
Wang Q, Shen X, Chen G, Du J. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation. International Journal of Cancer. 2023;153(4):709-722. doi:10.1002/ijc.34464
BibTeX
@article{Wang2023,
author = {Wang, Qianyu and Shen, Xiaofei and Chen, Gang and Du, Junfeng},
title = {How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation},
journal = {International Journal of Cancer},
year = {2023},
volume = {153},
number = {4},
pages = {709--722},
doi = {10.1002/ijc.34464}
}
EUVIMED